July 30, 2016 5:32 PM ET

Pharmaceuticals

Company Overview of Novartis Pharmaceuticals Corporation

Company Overview

Novartis Pharmaceuticals Corporation researches, develops, manufactures, and markets medicines and treatments for helping patients and improving patient care. It offers prescription drugs to treat various diseases and conditions, including cancer, cardiovascular, central nervous system, endocrine, inflammatory, ophthalmic, infectious, neurological, organ transplantation, psychiatric, respiratory, skin, and infectious diseases and conditions. The company also provides patient assistance programs to manage diseases and conditions. Novartis Pharmaceuticals Corporation was formerly known as Sandoz Pharmaceuticals Corporation and changed its name to Novartis Pharmaceuticals Corporation in March 1...

One Health Plaza

East Hanover, NJ 07936-1080

United States

Founded in 1968

Phone:

973-781-8300

Fax:

973-781-8265

Key Executives for Novartis Pharmaceuticals Corporation

President, US Country Head and President of Novartis Corporation
Chief Financial and Administrative Officer and Vice President
Chief Compliance Officer, Vice President and Us Country Head of Ethics & Compliance
Vice President, General Counsel and US Country Head of Legal
Vice President of Communications and US Country Head of Communications
Compensation as of Fiscal Year 2016.

Novartis Pharmaceuticals Corporation Key Developments

Novartis Pharmaceuticals - Special Call

Novartis Pharmaceuticals - Special Call

Novartis Pharmaceuticals Corporation Presents at NewYork BIO Annual Conference 2016, May-12-2016 01:45 PM

Novartis Pharmaceuticals Corporation Presents at NewYork BIO Annual Conference 2016, May-12-2016 01:45 PM. Venue: New York, United States. Speakers: Peter Waibel, Head US Patent Litigation.

Novartis Receives Three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes

Novartis announced that the US Food and Drug Administration (FDA) has granted three Breakthrough Therapy Designations for Ilaris® (canakinumab) to treat three rare types of Periodic Fever Syndromes, also known as Hereditary Periodic Fevers. This means Novartis will work closely with the FDA to expedite the regulatory review of Ilaris for these conditions. Periodic Fever Syndromes are a group of autoinflammatory diseases that cause disabling and recurrent fevers, which may be accompanied by joint pain and swelling, muscle pain and skin rashes, with complications that can be life-threatening. The FDA considers a treatment a Breakthrough Therapy if it is intended to treat a serious or life-threatening condition and preliminary evidence indicates it may be better than existing treatments. If approved, Ilaris will likely be the first medicine to gain approval from drug regulators for the treatment of TRAPS and HIDS/MKD, and it will be an alternative to the only FDA-approved treatment for FMF, colchicine. The Breakthrough Therapy Designations were granted based on the pivotal Phase III trial ("Canakinumab Pivotal Umbrella Study in Three Hereditary Periodic Fevers"). Based on this study Novartis submitted three supplemental Biologic License Applications in the US to register Ilaris for use in these indications.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Novartis Pharmaceuticals Corporation, please visit www.pharma.us.novartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.